Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Completed · Phase 3

Conditions studied: Acne Vulgaris

In brief

The study hypothesis are based on the assumption that : * CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects * CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable safety and tolerability profile

Key facts

Study ID

NCT01880320

Run by

Galderma R&D

People needed

503

Starts

2013-07-01

Expected to finish

2014-03-01

Last updated by the study team

2018-06-28

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, who is 12 years of age or older at Screening visit.
• Clinical diagnosis of acne vulgaris with facial involvement.
• An IGA of Moderate (3) or Severe (4) at Baseline visit.
• A minimum of 20 but not more than 100 inflammatory lesions (papules and pustules) on the face (including the nose) at Baseline visit.
• A minimum of 30 but not more than 150 non-inflammatory lesions (open comedones and closed comedones) on the face (including the nose) at Baseline visit.

You may not qualify if…

• More than 2 acne nodules on the face at Baseline visit.
• Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, or acne requiring systemic treatment.
• Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea. This includes clinically significant abnormal findings, uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results, and/or put the subject at significant risk (according to Investigator's judgment) if he/she participates in the clinical trial.
• The subject has received, applied or taken some specified treatments within the specified timeframe prior to the Baseline visit
• The subject is unwilling to refrain from use of prohibited medication during the clinical trial.
• Use of hormonal contraceptives solely for control of acne.

Where it is running

• Galderma Investigational site — Birmingham, Alabama, United States
• Galderma Investigationnal Site — Mobile, Alabama, United States
• Galderma investigational Site — Hot Springs, Arkansas, United States
• Galderma Investigational Site — Los Angeles, California, United States
• Galderma Investigational Site — Sacramento, California, United States
• Galderma Investigational Site — Santa Monica, California, United States
• Galderma Investigational Site — Miami, Florida, United States
• Galderma Investigational Site — Miramar, Florida, United States
• Galderma Investiogational Site — Newnan, Georgia, United States
• Galderma Investigational Site — Snellville, Georgia, United States
• Galderma Investigational Site — Chicago, Illinois, United States
• Galderma Investigational Site — Detroit, Michigan, United States
• Galderma Investigational Site — Albuquerque, New Mexico, United States
• Galderma Investigational Site — New York, New York, United States
• Galderma Investigational Site — Stony Brook, New York, United States
• Galderma Investigational Site — Raleigh, North Carolina, United States
• Galderma Investigational Site — Beachwood, Ohio, United States
• Galderma investigational Site — Hershey, Pennsylvania, United States
• Galderma Investigational Site — Greenville, South Carolina, United States
• Galderma Investigational Site — Goodlettsville, Tennessee, United States
• Galderma Investigational Site — Knoxville, Tennessee, United States
• Galderma Investigational Site — Arlington, Texas, United States
• Galderma Investigational Site — San Antonio, Texas, United States
• Galderma Investigational Site — Salt Lake City, Utah, United States
• Galderma Investigational Site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.